177 related articles for article (PubMed ID: 24498115)
1. Bactericidal activity of an imidazo[1, 2-a]pyridine using a mouse M. tuberculosis infection model.
Cheng Y; Moraski GC; Cramer J; Miller MJ; Schorey JS
PLoS One; 2014; 9(1):e87483. PubMed ID: 24498115
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel 1,2,3-triazole analogues of Imidazo-[1,2-a]-pyridine-3-carboxamide against Mycobacterium tuberculosis.
Nandikolla A; Srinivasarao S; Khetmalis YM; Kumar BK; Murugesan S; Shetye G; Ma R; Franzblau SG; Sekhar KVGC
Toxicol In Vitro; 2021 Aug; 74():105137. PubMed ID: 33684466
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of liposomes containing 4-(5-pentadecyl-1,3,4-oxadiazol-2-yl)pyridine in a murine model of progressive pulmonary tuberculosis.
Mata-Espinosa D; Molina-Salinas GM; Barrios-Payán J; Navarrete-Vázquez G; Marquina B; Ramos-Espinosa O; Bini EI; Baeza I; Hernández-Pando R
Pulm Pharmacol Ther; 2015 Jun; 32():7-14. PubMed ID: 25843004
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents.
Wang A; Lv K; Li L; Liu H; Tao Z; Wang B; Liu M; Ma C; Ma X; Han B; Wang A; Lu Y
Eur J Med Chem; 2019 Sep; 178():715-725. PubMed ID: 31229874
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity studies of side chain analogues of the anti-tubercular agent, Q203.
Kang S; Kim YM; Kim RY; Seo MJ; No Z; Nam K; Kim S; Kim J
Eur J Med Chem; 2017 Jan; 125():807-815. PubMed ID: 27750198
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of novel imidazo[1,2-a]pyridinecarboxamides as potent anti-tuberculosis agents.
Onajole OK; Lun S; Yun YJ; Langue DY; Jaskula-Dybka M; Flores A; Frazier E; Scurry AC; Zavala A; Arreola KR; Pierzchalski B; Ayitou AJ; Bishai WR
Chem Biol Drug Des; 2020 Dec; 96(6):1362-1371. PubMed ID: 32515129
[TBL] [Abstract][Full Text] [Related]
7. Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates.
Moraski GC; Oliver AG; Markley LD; Cho S; Franzblau SG; Miller MJ
Bioorg Med Chem Lett; 2014 Aug; 24(15):3493-8. PubMed ID: 24909079
[TBL] [Abstract][Full Text] [Related]
8. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antitubercular evaluation of reduced lipophilic imidazo[1,2-a]pyridine-3-carboxamide derivatives.
Wang H; Wang A; Gu J; Fu L; Lv K; Ma C; Tao Z; Wang B; Liu M; Guo H; Lu Y
Eur J Med Chem; 2019 Mar; 165():11-17. PubMed ID: 30654236
[TBL] [Abstract][Full Text] [Related]
10. Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.
Kang S; Kim RY; Seo MJ; Lee S; Kim YM; Seo M; Seo JJ; Ko Y; Choi I; Jang J; Nam J; Park S; Kang H; Kim HJ; Kim J; Ahn S; Pethe K; Nam K; No Z; Kim J
J Med Chem; 2014 Jun; 57(12):5293-305. PubMed ID: 24870926
[TBL] [Abstract][Full Text] [Related]
11. Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds.
Moraski GC; Deboosère N; Marshall KL; Weaver HA; Vandeputte A; Hastings C; Woolhiser L; Lenaerts AJ; Brodin P; Miller MJ
PLoS One; 2020; 15(1):e0227224. PubMed ID: 31905374
[TBL] [Abstract][Full Text] [Related]
12. Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3.
Remuiñán MJ; Pérez-Herrán E; Rullás J; Alemparte C; Martínez-Hoyos M; Dow DJ; Afari J; Mehta N; Esquivias J; Jiménez E; Ortega-Muro F; Fraile-Gabaldón MT; Spivey VL; Loman NJ; Pallen MJ; Constantinidou C; Minick DJ; Cacho M; Rebollo-López MJ; González C; Sousa V; Angulo-Barturen I; Mendoza-Losana A; Barros D; Besra GS; Ballell L; Cammack N
PLoS One; 2013; 8(4):e60933. PubMed ID: 23613759
[TBL] [Abstract][Full Text] [Related]
13. Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
Singh S; Roy KK; Khan SR; Kashyap VK; Sharma A; Jaiswal S; Sharma SK; Krishnan MY; Chaturvedi V; Lal J; Sinha S; Dasgupta A; Srivastava R; Saxena AK
Bioorg Med Chem; 2015 Feb; 23(4):742-52. PubMed ID: 25614114
[TBL] [Abstract][Full Text] [Related]
14. Functionalized 3-amino-imidazo[1,2-a]pyridines: a novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors.
Odell LR; Nilsson MT; Gising J; Lagerlund O; Muthas D; Nordqvist A; Karlén A; Larhed M
Bioorg Med Chem Lett; 2009 Aug; 19(16):4790-3. PubMed ID: 19560924
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis.
Tantry SJ; Markad SD; Shinde V; Bhat J; Balakrishnan G; Gupta AK; Ambady A; Raichurkar A; Kedari C; Sharma S; Mudugal NV; Narayan A; Naveen Kumar CN; Nanduri R; Bharath S; Reddy J; Panduga V; Prabhakar KR; Kandaswamy K; Saralaya R; Kaur P; Dinesh N; Guptha S; Rich K; Murray D; Plant H; Preston M; Ashton H; Plant D; Walsh J; Alcock P; Naylor K; Collier M; Whiteaker J; McLaughlin RE; Mallya M; Panda M; Rudrapatna S; Ramachandran V; Shandil R; Sambandamurthy VK; Mdluli K; Cooper CB; Rubin H; Yano T; Iyer P; Narayanan S; Kavanagh S; Mukherjee K; Balasubramanian V; Hosagrahara VP; Solapure S; Ravishankar S; Hameed P S
J Med Chem; 2017 Feb; 60(4):1379-1399. PubMed ID: 28075132
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.
Yoshimatsu T; Nuermberger E; Tyagi S; Chaisson R; Bishai W; Grosset J
Antimicrob Agents Chemother; 2002 Jun; 46(6):1875-9. PubMed ID: 12019103
[TBL] [Abstract][Full Text] [Related]
17. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and antitubercular evaluation of novel dibenzo[b,d]thiophene tethered imidazo[1,2-a]pyridine-3-carboxamides.
Pulipati L; Sridevi JP; Yogeeswari P; Sriram D; Kantevari S
Bioorg Med Chem Lett; 2016 Jul; 26(13):3135-3140. PubMed ID: 27184765
[TBL] [Abstract][Full Text] [Related]
19. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.
Ahmad Z; Tyagi S; Minkowsk A; Almeida D; Nuermberger EL; Peck KM; Welch JT; Baughn AS; Jacobs WR; Grosset JH
Indian J Med Res; 2012 Nov; 136(5):808-14. PubMed ID: 23287128
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, molecular docking and anti-mycobacterial evaluation of new imidazo[1,2-a]pyridine-2-carboxamide derivatives.
Jose G; Suresha Kumara TH; Nagendrappa G; Sowmya HB; Sriram D; Yogeeswari P; Sridevi JP; Guru Row TN; Hosamani AA; Sujan Ganapathy PS; Chandrika N; Narendra LV
Eur J Med Chem; 2015 Jan; 89():616-27. PubMed ID: 25462270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
